Literature DB >> 22219473

Renal impairment and transapical aortic valve implantation: impact of contrast medium dose on kidney function and survival.

Navid Madershahian1, Maximilian Scherner, Oliver Liakopoulos, Parwis Rahmanian, Elmar Kuhn, Martin Hellmich, Jochen Mueller-Ehmsen, Thorsten Wahlers.   

Abstract

OBJECTIVE: Patients undergoing transapical aortic valve implantation (TA-AVI) are usually over 80 years old and have a high prevalence of chronic kidney disease. However, transcatheter valve therapies require the use of contrast injections with the risk of nephrotoxicity. The aim of this study was to evaluate post-operative kidney function and survival in patients with pre-existing renal impairment with regard to the amount of contrast media used during TA-AVI.
METHODS: From January 2008 to March 2011, 50 patients (52% females, mean age 80.7 ± 5.3 years) with a serum creatinine level of >1.3 mg/dl were investigated. Patients receiving a dose of <100 ml of a contrast agent (low-dose group, n = 24) were separated from those who received >100 ml of a contrast agent (high-dose group, n = 26). An acute contrast-induced nephropathy (CIN) was defined as a serum creatinine increase of 0.5 mg/dl or by >25% of a baseline value within 48 h from contrast medium administration. Patients in both groups had similar characteristics in terms of age, sex, body mass index and comorbidities.
RESULTS: The median pre-contrast creatinine was 1.67 (1.37-1.83) mg/dl in the low-dose group and 1.51 (1.26-1.98) mg/dl in the high-dose group (P = 0.76). The post-contrast creatinine at 48 h was 1.53 (1.33-2.05) and 2.29 (1.67-2.86) mg/dl in the groups receiving low- and high-dose contrast agents, respectively (P = 0.007). CIN occurred in 41.7% (n = 10) of patients in the low-dose contrast group and in 69.2% (n = 18) in the high-dose contrast group (P = 0.046). Haemodialysis is necessary for 16.7% of the low-dose group and 38.5% of the high-dose group (P = 0.12). Trends towards longer intensive care unit and hospital stay were seen in patients with an extensive use of contrast media [4.3 (2.5-6.5) vs. 5 (3-7.8) days and 12 (9-14.3) vs. 13 (9-18) days, P = 0.091 vs. P = 0.546, respectively]. Regarding death, 3-month and 3-year mortality were significantly higher in the high-dose group (8.3 vs. 30.8%, P = 0.036 and 25 vs. 61.5%, P = 0.004, respectively).
CONCLUSIONS: Our results indicate a possible association between higher CIN and mortality rate and the extensive use of contrast media during TA-AVI among high-risk patients with pre-existing renal impairment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22219473     DOI: 10.1093/ejcts/ezr199

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  10 in total

Review 1.  Acute kidney injury after transcatheter aortic valve implantation.

Authors:  Maximilian Scherner; Thorsten Wahlers
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

2.  Association of blood transfusion with acute kidney injury after transcatheter aortic valve replacement: A meta-analysis.

Authors:  Charat Thongprayoon; Wisit Cheungpasitporn; Erin A Gillaspie; Kevin L Greason; Kianoush B Kashani
Journal:  World J Nephrol       Date:  2016-09-06

Review 3.  Advanced chronic kidney disease: Relationship to outcomes post-TAVR, a meta-analysis.

Authors:  Nader Makki; Scott M Lilly
Journal:  Clin Cardiol       Date:  2018-07-18       Impact factor: 2.882

4.  Improvement in renal functions with transcatheter aortic valve implantation.

Authors:  Telat Keleş; Hüseyin Ayhan; Tahir Durmaz; Cenk Sarı; Abdullah Nabi Aslan; Kemal Eşref Erdoğan; Hacı Ahmet Kasapkara; Emine Bilen; Nihal Akar Bayram; Murat Akçay; Engin Bozkurt
Journal:  J Geriatr Cardiol       Date:  2013-12       Impact factor: 3.327

Review 5.  Impact of renal dysfunction on mid-term outcome after transcatheter aortic valve implantation: a systematic review and meta-analysis.

Authors:  Chi Chen; Zhen-Gang Zhao; Yan-Biao Liao; Yong Peng; Qing-Tao Meng; Hua Chai; Qiao Li; Xiao-Lin Luo; Wei Liu; Chen Zhang; Mao Chen; De-Jia Huang
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

Review 6.  Transcatheter aortic valve implantation.

Authors:  Thomas M Snow; Neil Moat; Sarah Barker; Alison Duncan; Carlo Di Mario
Journal:  Glob Cardiol Sci Pract       Date:  2012-08-30

7.  Balloon expandable transcatheter aortic valve implantation via the transfemoral route with or without pre-dilation of the aortic valve - rationale and design of a multicentre registry (EASE-IT TF).

Authors:  Christian Butter; Peter Bramlage; Tanja Rudolph; Claudius Jacobshagen; Jürgen Rothe; Hendrik Treede; Sebastian Kerber; Derk Frank; Lenka Seilerova; Gerhard Schymik
Journal:  BMC Cardiovasc Disord       Date:  2016-11-15       Impact factor: 2.298

8.  Acute Kidney Injury Following Transcatheter Aortic Valve Implantation: Association with Contrast Media Dosage and Contrast Media Based Risk Predication Models.

Authors:  Doron Sudarsky; Yarden Drutin; Fabio Kusniec; Liza Grosman-Rimon; Ala Lubovich; Wadia Kinany; Evgeni Hazanov; Michael Gelbstein; Edo Y Birati; Ibrahim Marai
Journal:  J Clin Med       Date:  2022-02-23       Impact factor: 4.241

9.  The risk of acute kidney injury and its impact on 30-day and long-term mortality after transcatheter aortic valve implantation.

Authors:  Katrin Gebauer; Gerhard-Paul Diller; Gerrit Kaleschke; Gregor Kerckhoff; Nasser Malyar; Matthias Meyborg; Holger Reinecke; Helmut Baumgartner
Journal:  Int J Nephrol       Date:  2012-12-26

Review 10.  Transcatheter Aortic Valve Replacement: a Kidney's Perspective.

Authors:  Wisit Cheungpasitporn; Charat Thongprayoon; Kianoush Kashani
Journal:  J Renal Inj Prev       Date:  2016-01-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.